IL6 and adult-onset Still disease: Another study by Yuko Kaneko et al. demonstrated that inhibiting interleukin-6 (IL-6) with tocilizumab is effective for patients with adult-onset Still’s disease (AOSD) refractory to glucocorticoid therapy [9].